A Tale Of Two Giants; Tracking India And China’s Rise In The Pharmaceutical Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The nature of business relationships between multinational pharma companies and Indian and Chinese firms varies significantly, according to a recent study released by the Ewing Marion Kauffman Foundation
You may also be interested in...
Ranbaxy Files For Phase I Trial On First Compound From GSK Deal
MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials
Ranbaxy Files For Phase I Trial On First Compound From GSK Deal
MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials
GNI And EpiCept Ink Development Deal For Anti-Viral Hepatitis B Drug
SHANGHAI - GNI and EpiCept have entered into an agreement that will see the latter develop a new anti-viral hepatitis B drug, EP1013, in Asia, Australia and New Zealand